Although accounts of neurological complica tions resulting from the use of neuroleptic drugs have consistently appeared in the psychiatric literature since the introduction of reserpine in the 1930's, serious concern about the perma nence of these effects has been a rather recent development. As early as 1956, reports by Ey, Faure, and Rappard (io) and by Hall, Jackson, and Swain (i 3) called attention to the persist ence of extrapyrarnidal symptoms several months after the cessation of extended chiorpromazine treatment.
Emphasis on the persistence of dyskinetic symptoms ter extended treatment subsequently appeared in reports by Broussolle and Rosier (2) â€˜¿ tardive dyskinesia'. According to a recent review by Crane (k), more than thirty publications have appeared reporting neurological disorders characterized by dyskinetic movements in the bucco-lingual area and extremities of chronic mental patients given major neuroleptics over prolonged periods. Although dyskinesia is reported to occur in all regions of the body (7, 8, II, 12, 14) and in various clinical forms (choreic, athetotic, ballistic, and myoclonic (7), it is identified in more distinct and unique ways with orofacio lingual movements (12, 24). These involve rhythmical forward, backward, and at times lateral movements of the tongue, either pro truding between the teeth and lips or pushing against the dental arch and cheeks. Lip smack ing and chewing movements are added features in some patients. The incidence rate of this type of â€˜¿ irreversible' dyskinesia among chronic hospital populations has been reported as ranging from 10 to 23 per cent (i i), although a recent report claims only rare occurrence (15). Part of the reason for this discrepancy lies in the lack of systematic investigation and follow-up information and in the difficulty in differ entiating drug-induced from naturally occurring symptoms among the population in question.
The claimed irreversibility of drug-induced dyskinesia is an especially controversial issue. Evidence from numerous independent sources has consistently revealed lack of improvement in the dyskinetic symptoms of a large percentage of patients during drug-free periods following prolonged neuroleptic drug treatment (@,6, I 7,
22).
Further, the results of at least three separately conducted studies have shown anti parkinson drugs to be of little value in reversing such symptoms (9, i6, 23). In spite of this evidence, and the claim by some authors that dyskinesia is the outcome of irreversible changes in the central nervous system (7, I I, 14), Kline (is) insists that irreversibilityhas not been satisfactorily demonstrated in previously re ported cases in the literature and that there is a lack of convincing evidence from long-term follow-up studies.
In view of these issues, the authors undertook the present study to observe and rate the extra pyramidal symptoms of patients with tardive dyskinesia for a period of approximately one year. Specific aims were to investigate drug induced motor disturbances in as systematic and quantitative a manner as possible in order to clarify the relationship of these abnormal movements to: (I) the cessation of neuroleptic medication;
(2) increases in dosage levels; 6o6 TARDIVE DYSKINESIA:ITS RELATION TO NEUROLEPTIC AND ANTIPARKINSONDRUGS and (@) the use of antiparkinson agents.
METHOD
Eighty-eight chronic hospital in-patients were reported as exhibiting symptoms of tardive dyskinesia in a recent survey conducted by Crane at Spring Grove State Hospital. For present purposes, a detailed medical-psychiatric record, emphasizing family and personal histo ries of neurological and psychiatric illness, was obtained on these and other later selected cases. Conventional neurological examinations were performed on the patients, and their clinical laboratory records were examined for evidence of liver dysfunction. On the basis of this material, cases with previous, non-drug-related physical conditions having a major bearing on the present dyskinetic symptoms were eliminated from further study.
From a resulting sample of 56 patients, three groups were formed on the basis of the treatment they were receiving at the start of the study: Following an initial two-week stabilization period, Phase I through IV lengths were 10, 12, 10, and 12 weeks respectively. Throughout the entire study period, the original drug-free group served as a control group and was not given neuroleptic medication of any sort (Coded O@O@O@O).*For drug-treated patients, medication for the second and fourth phases was changed, while medication for the third phase was the same as that for the first. Except for one condition, assignment of these patients to various treatment schedules was non systematic. For overriding clinical reasons, a few patients on high dosages of neuroleptic drugs were placed in the drug control group. The treatment schedules, illustrated in Table I , are described below: Of the 32 patients initially receiving neuro leptic drugs alone, one sub-group of i 6 con tinued to receive their original drugs through out the study. Dosage for 8 of these i 6 patients was left unchanged (the drug-control group, coded N-N-N-N), while that for the other 8 patients was doubled during the second and fourth phases (N-2N-N-2N ). The second group of 16 were placed on interrupted drug schedules: medication for 8 of these cases was discontinued suddenly during the second phase and gradually during the fourth phase ((N-O-N-O)SG);
for the remaining 8 cases, this sequence was reversed
Of the i6 patients originally on neuroleptics combined with trihexyphenidyl, 8 were giving antiparkinson medication alone during the second phase and neuroleptic medication alone during the fourth phase (NA-A-NA-N). Again, this sequence was reversed for the remaining 8 patients (NA-N-NA-A).
Assessments of the dyskinetic symptoms of all patients were made on a bi-weekly basis by neurologically trained investigators (I.T. and M.B.) thoroughly familiar with the symptoms of tardive dyskinesia.
Unlike the latter rater (M.B.) who was blind, the principal investi gator (I.T.), responsible for symptom assess ments in approximately three-fourths of the cases, also determined group assignment and the prescription of medication. At the end of each treatment phase, the blind rater made assess ments of the symptoms of all cases. At these times also motion pictures were taken of 12 of the study's most prominent cases and were later rated under blind conditions for degree of dyskinetic symptom display by another of the present authors (A.K.). Mean ratings for each of the four treatment phases were determined by averaging the bi weekly symptom assessments. Differences be tween phases in these and in end-of-phase mean ratings for each subgroup were then examined by t for correlated means. Linear and cubic trends in mean results over the four treatment periods for each subgroup were determined by 
RESULTS
Characteristics of the total and various sub samples are presented in Table II .
The majority of patients were between 50 and 70 years of age; the mean age was 6o. The male/ female ratio was 4 to 3. Most (7i per cent) of the patients were schizophrenic; the rest were classified as either mentally defective with psychosis or as displaying a chronic brain syndrome. The drug-free control group tended to be oJder (differing significantly from two of the experimental groups), and the drug-control group was composed solely of male patients, a result partially attributable to dosage deter mined assignment to this particular subgroup. o.2.@l
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54 (9) 58 (7) 62 (9) 63 (13) 55 (7) 62 (12) Product-moment correlations between dyski netic symptom severity and the variables, total drug intake and number of years on medication, were non-significant for both â€˜¿ total body' and head symptoms. This lack of relationship between symptom severity and drug usage agrees with the finding of Brandon, McClelland and Protheroe that the risk of facial dyskinesia was unrelated to total duration of exposure or to total drug dosage in those mental hospital patients over the age of 50 who were subjected to phenothiazine treatment (24). Although a formal analysiswas not undertaken because of sample limitations,there was no apparent relationship between the specific drug involved in each case and symptom severity. Also, there was no evidence of a relationship between initial measure of drug usage and subsequent reactivity under the various experimental conditions of the study.
Treatment effects
Five patientsfailedto complete the study. Two (N-0-N-O)SG patientsbecame disturbed during their drug-free intervals (both second and fourth phases) and were placed on medica tion, and a third was discharged from the hospital before completion. One NA-A-NA-N patient became disturbed when her pheno thiazine drug was withdrawn, and one NA-N-NA-A patient was transferred to another state psychiatric hospital.
Preliminary examination of dyskinetic symp tom results revealed that sensitivity to treatment effects was almost exclusively in the area of the mouth, tongue and cheeks. Evaluation of symptoms involving upper and lower extremities were progressively less sensitive in that order, and neither was included in subsequent analyses. Mean ratings of head symptoms over the four treatment phases are presented in Table III .
Mean bi-weekly ratings: Except for the drug discontinuance groups, differences between mean severity scores for adjacent phases were non-significant.
In five of the six instances in which neuroleptic drugs were discontinued, there was a significant rise in dyskinetic symp tomatology during the drug-free period. In the sixth instance there was a tendency toward significance in the same direction. In two of three instances in which neuroleptic drugs were reinstated, there was a significant drop in symptomatology for the subsequent medication period. Interestingly, the administration of the antiparkinson agent had little bearing on dyskinetic symptom display.
Since sudden and gradual discontinuance did not differentially affect the emergence of dyski netic symptoms, the N-O-N-O groups of Table  III were free status, with greater severity. In each case, the extent of change in severity of symptoms from one adjacent phase to another in the N-O-N-O sequence was significant, yielding a cubic trend component over the four phases that was significant at the @oilevel. In com parison, a corresponding analysis over the four treatment phases for the remaining groups yielded no significant cubic trend components.
End-of-phase ratingsâ€"Blind rater: Mean severity ratings for the independent, blind observer obtained at the end of each treatment phase (Table III) instance, that for the third and fourth phases of the combination drug group whose neuroleptic drug was discontinued after the third phase (NA-N-NA-A). Considering patients from both single and combination drug groups whose neuroleptic medications were discontinued after the first phase, there was a tendency for mean symptom severity to increase at the end of the second, or neuroleptic drug-free, phase (2@8g vs.
3@72, t = . 74, p = . i o).
There was also a significant (.05 level) rise in mean symptom level between the third and fourth phases for those patients whose neuroleptic medications were discontinued after the third phase, which largely reflected the above change in severity for this same period in the combined drug group. The former authors noted that, paradoxically, the withdrawal of phenothiazines did not produce an alleviation in dyskinetic symptoms, and that subsequent return to the same or similar medication resulted in slight improve ment over drug-free conditions. Crane and his co-workers reported that neurological symptoms were aggravated during the first two weeks of the drug-free period, although alleviation of symptoms subsequently occurred in some patients after a drug-free period of ten weeks. 
